PR Newswire (press release) The SmPC is available at www.pixuvri.eu. CTI is currently accruing patients into a Phase 3 trial comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. PIXUVRI does not have marketing approval in the ...
4-traders (press release) The SmPC is available at www.pixuvri.eu. CTI is currently accruing patients into a Phase 3 trial comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. PIXUVRI does not have marketing approval in the ... and more »
NASDAQ Before joining Johnson & Johnson, Mr. Carchedi played a key role in commercializing a number of oncology products, including GEMZAR® ( gemcitabine ) at Eli Lilly & Company, as well as TAXOL® (paclitaxel) and PARAPLATIN® (carboplatin) at Bristol ... and more »
Toronto Star The bids do not include the cost of the drugs in question — cyclophosphamide and gemcitabine — which are commonly used to treat cancers of the breast and lymphatic system. Asked by Tory MPP Jane McKenna to account for the “huge difference in pricing ... and more »
OncLive The publication of the OCEANS trial resulted in an addition to the guidelines of the regimen of carboplatin/ gemcitabine / bevacizumab to the list of acceptable recurrence therapies. We'll have more clarity next year when the results of the AURELIA trial ...
The Herald | HeraldOnline.com The SmPC is available at www.pixuvri.eu. CTI is currently accruing patients into a Phase 3 trial comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. PIXUVRI does not have marketing approval in the ... and more »
Hamilton Spectator The bids do not include the cost of the drugs in question — cyclophosphamide and gemcitabine — commonly used to treat cancers of the breast and lymphatic system. Asked by Tory MPP Jane McKenna to account for the "huge difference in pricing," Zaffiro ... and more »
Seeking Alpha The primary objective of this study is to assess overall survival (OS) in pancreatic cancer patients with borderline resectable or locally advanced unresectable pancreatic cancer who will receive a regiment of FOLFIRINOX (5-fluorouracil [5-FU ...
